Feasibility and safety of rapid glofitamab ramp-up
Diffuse large B-cell lymphoma (DLBCL) is clinically and molecularly a heterogeneous disease with recognized transcriptional (germinal center B-cell-type, GCB; activated B-cell-type, ABC) and genetic subtypes (DLB class , LymphGen) [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]. State-of-the-art immunochemotherapy cures approximately 75% of patients [ 8 ]. Refractory or relapsed disease (r/r LBCL) is often characterized by rapid lymphoma proliferation and clinical need for fast-acting treatments. Prognosis in r/r LBCL is substantially diminished despite the use of engineered autologous T-cells with a CD19-targeting chimeric antigen receptor (CAR-T) [ 9 ]. Notably, approximately 50% of patients relapse after or are refractory to CD19-directed CAR-T-cell therapy with different determinants of resistant disease, highlighting the medical need for treatment optimization following CAR-T [ 10 , 11 ].
Authors
- Marion Subklewe (ORCID: https://orcid.org/0000-0001-9154-9469)
- Konstantinos Christofyllakis (ORCID: https://orcid.org/0000-0002-0308-388X)
- Marie Anne‐Catherine Neumann (ORCID: https://orcid.org/0000-0002-2396-6110)
- David Böckle (ORCID: https://orcid.org/0000-0002-1783-9641)
- Ulrich Bernd Keller (ORCID: https://orcid.org/0000-0002-8485-1958)
- Hans Christian Reinhardt (ORCID: https://orcid.org/0000-0001-5706-9349)
- Marcel Teichert
- Georg Lenz (ORCID: https://orcid.org/0000-0002-4728-1693)
- Bastian von Tresckow (ORCID: https://orcid.org/0000-0003-1410-4487)
- Vladan Vučinić (ORCID: https://orcid.org/0000-0002-8398-285X)
- Thomas Pabst (ORCID: https://orcid.org/0000-0002-6055-5257)
- Susanne Ghandili (ORCID: https://orcid.org/0000-0001-5655-3155)
- Joseph Kauer (ORCID: https://orcid.org/0000-0003-1632-0167)
- Fabian Görke (ORCID: https://orcid.org/0009-0007-3452-0660)
- Urban Novak (ORCID: https://orcid.org/0000-0001-7642-2101)
- Bjoern Chapuy (ORCID: https://orcid.org/0000-0002-6485-8773)
- Thomas Melchardt (ORCID: https://orcid.org/0000-0002-0122-3631)
- P Borchmann
- Francis Ayuk (ORCID: https://orcid.org/0000-0001-6297-1847)
- Celine Huajia Liem (ORCID: https://orcid.org/0009-0000-6597-9692)
- Peter Dreger (ORCID: https://orcid.org/0000-0002-7429-8570)
- Evgenii Shumilov (ORCID: https://orcid.org/0000-0003-0178-1729)
- Nina Malburg
- Giulia Magno (ORCID: https://orcid.org/0009-0008-6006-4758)
- Christiane Pott (ORCID: https://orcid.org/0009-0005-9260-8340)
- Tim Versteegen
- Rebecca Wurm-Kuczera
- Merle Klein Helmkamp
- Antonia Busse
Institutions
- University of Bern (CH)
- Alliance University (IN)
- Universität Hamburg (DE)
- Genetic Alliance (US)
- University of Cologne (DE)
- Max Delbrück Center (DE)
- Heidelberg University (DE)
- Paracelsus Medical University (AT)
- University Hospital of Bern (CH)
- University Hospital Heidelberg (DE)
- Humboldt-Universität zu Berlin (DE)
- Düsseldorf University Hospital (DE)
- German Cancer Society (DE)
- University Hospital Münster (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital Schleswig-Holstein (DE)
- Essen University Hospital (DE)
- University Hospital Leipzig (DE)
- Fraunhofer Institute for Cell Therapy and Immunology (DE)
- University Hospital Cologne (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Duisburg-Essen (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
- Saarland University (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Leukemia
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1038/s41375-026-03003-3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Deutschen Konsortium für Translationale Krebsforschung
- Berlin Institute of Health